Abstract

High prevalence and inferior long-term outcomes for TP53 mutations in therapy-related acute lymphoblastic leukemia.

Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call